PCSK9 and cardiovascular disorder: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA; target of statins) reductase, Niemann-Pick C1-Like 1 (NPC1L1; target of ezetimibe) and proprotein convertase subtilisin/kexin type 9 (PCSK9; target of PCSK9 inhibitors) are common targets of low-density lipoprotein cholesterol (LDL-C)-lowering drugs for the prevention of cardiovascular disease [5].